The availability of the non-vitamin K antagonist oral anticoagulants (NOACs) has transformed the landscape for the prevention of atrial fibrillation (AF)-related stroke. Nonetheless, all of the NOACs have a degree of renal excretion, ranging from the highest being for dabigatran (80% renal excreted) to 50% for edoxaban, to 33% for rivaroxaban, and to 27% for apixaban. 1 In contrast, warfarin is eliminated principally through hepatic metabolism and is not directly renally excreted. 2 Patients with AF and impaired renal function are at high risk of stroke, thromboembolism, myocardial infarction (MI), death, and serious bleeding. 3 In patients with supranormal renal function, with estimated glomerular filtration rate N95 mL/min, some concern has been expressed for less efficacy in ischemic stroke prevention, seen in a post hoc subgroup exploratory analyses for edoxaban by the United States FDA.
The ENSURE-AF study (ClinicalTrials.gov Identifier: NCT02072434) of anticoagulation for electrical cardioversion in nonvalvular atrial fibrillation (NVAF) showed comparable low rates of bleeding and thromboembolism between the edoxaban and the enoxaparin-warfarin treatment arms. 6 In this post hoc analysis from ENSURE-AF, we investigated the relationship between renal function and blinded adjudicated outcomes.
Methods
ENSURE-AF was a multicenter, PROBE evaluation trial of edoxaban 60 mg once daily or dose adjusted to 30 mg/d if weight ≤60 kg, creatinine clearance (CrCl) ≤50 mL/min, and/or concomitant use of P-glycoprotein inhibitors compared with therapeutically monitored enoxaparin-warfarin in 2,199 patients with NVAF of at least 48 hours and no longer than 12 months undergoing electrical cardioversion. 7 By protocol and as published previously, 6,7 patients were stratified according to cardioversion approach (Transesophageal Echocardiography or non-TEE) as determined by the local investigator. In the TEE-guided stratum, both the TEE and cardioversion had to be performed within 3 days of randomization. Patients in the warfarin arm with international normalized ration (INR) b2 started treatment with a minimum of 1 dose each of enoxaparin and warfarin before cardioversion, and these drugs were continued until INR ≥2 was obtained. After a therapeutic range was achieved, patients were to discontinue enoxaparin and continue warfarin until end of treatment (day 28 following the procedure). Patients randomized to the edoxaban arm had to start treatment at least 2 hours prior to electrical cardioversion. The next dose of edoxaban was taken the day after cardioversion and then continued on a 24-hour cycle until day 28 postcardioversion. Patients with thrombi on TEE had a choice of completing 28 days of study treatment without cardioversion or being discontinued from the study. All patients were followed up for safety for another 30 days after completing or discontinuing the treatment. In all patients in the non-TEE-guided stratum, electrical cardioversion was performed at a minimum of 21 days following the start of treatment. Patients in the enoxaparinwarfarin arm received anticoagulation for a minimum of 21 days from the day of randomization. Patients with an INR b2 at randomization received enoxaparin and daily warfarin until the INR was ≥2 0. At that time, enoxaparin was discontinued and warfarin continued for the duration of the study. In the edoxaban arm, patients received edoxaban for a minimum of 21 days before cardioversion followed by the procedure and an additional 28 days of treatment. All patients in the non-TEE-guided strategy were followed for safety for 30 days after completing treatment.
Patients were also stratified according to prior experience in taking anticoagulants at the time of randomization (ie, anticoagulant experienced or anticoagulant naive) and selected edoxaban dose (60-mg QD dose or reduced 30-mg QD dose).
Briefly, categorical evaluation based on renal function was assessed at baseline and at the end of treatment, as per the clinical trial protocol The primary efficacy analysis was comparing the occurrence of a composite end point of stroke, systemic embolic event (SEE), MI, and cardiovascular (CV) death between the edoxaban group and the enoxaparinwarfarin group from randomization to end of follow-up and was performed on the intention-to-treat population: all individuals who were enrolled into the study and randomly assigned.
The primary safety end point of the trial was the composite of major + clinically relevant nonmajor (CRNM) bleeding which occurred during the on-treatment period, defined as the time period the patient was taking study medication plus up to 3 days after the last dose for that time period. Any bleeding was defined as the composite of major + CRNM + minor bleeding from time of first administration of study drug to end of treatment + 3 days. Patients were followed for 28 days on study drug after cardioversion plus another 30 days to assess safety on an investigator-prescribed standard of care.
Efficacy and safety outcomes and time in therapeutic range (TiTR) in the warfarin arm were analyzed in relation to CrCl in prespecified ranges of ≥15 and ≤30, N30 and ≤50, N50 and b80, and ≥80 mL/min, and an exploratory ≥95-mL/min analysis. The same outcome parameters were also assessed with CrCl as a continuous variable.
Statistical methods
Time in therapeutic range for a patient is defined as the percent of time sustained in INR therapeutic range (2.0 ≥ INR ≤ 3.0) from the first date of achieving 2.0 ≥ INR ≤ 3.0 during the on-treatment period. Mean TiTR was shown for all renal function strata. Demographic and baseline characteristics were summarized by treatment group and renal function stratum. Descriptive statistics were presented for the baseline CrCl and the change from baseline to end of treatment. The difference of the change from baseline between 2 treatment groups was assessed using an analysis of variance model. Frequency and percentage of patients with worsening renal function at the end of treatment were presented and compared using χ 2 test. The associations of CrCl strata with other binary variables and ordinal variables were evaluated by Cochran-Armitage trend test and Spearman Figure 1 correlation coefficient, respectively. Breslow-Day-Tarone test was performed to assess homogeneity of odds ratio across CrCl strata.
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Results
A total of 1,095 subjects were randomized to edoxaban and 1,104 to enoxaparin-warfarin. Mean age was 64.3 ± 10 and 64.2 ± 11 years, respectively, and overall mean CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 Table I in relation to CrCl strata. Mean age and the proportion of women progressively increased as CrCl decreased (P b .0001 for both variables). The proportions of paroxysmal and persistent AF were fairly similar across all CrCl strata. More comorbidities, such as heart failure, were generally more common in those with low CrCl (≤50), leading to a higher stroke risk, as reflected by higher mean CHA 2 DS 2 -VASc score. Higher mean HAS-BLED score was evident in those with CrCl ≤50.
Efficacy and safety end points in relation to renal function strata and treatment allocation are shown in Table II . Mean TiTR was progressively lower with reducing CrCl strata, being 66.8% in those with CrCl N30 to ≤50 compared with 71.8% in those with CrCl ≥80, although this trend was not statistically significant (P = .199).
The odds ratios for the primary efficacy and safety end points were comparable for the different predefined (≥15 to ≤30, N30 to ≤50, N50 to b80, ≥80) renal function strata; given the small numbers, the 95% CI included 1.0. In the subset of those with CrCl ≥95, the odds ratios showed consistency with the other CrCl strata.
When CrCl was assessed as a continuous variable, there was a nonstatistically significant trend toward higher events in the efficacy analysis (composite of stroke, SEE, MI, and CV death) and in the safety analysis (major + CRNM bleeding) with reducing CrCl levels (Figures 1  and 2) , with no significant differences between the 2 treatment arms. When we assessed CrCl at baseline compared with end of treatment, there were no significant differences in CrCl change between the edoxaban and enoxaparin-warfarin arms. The proportions with worsening of renal function (defined as a decrease of N20% from baseline) were similar in the 2 treatment arms (Table III) .
Discussion
In this ancillary analysis from ENSURE-AF, our principal findings are the following: (1) as renal function declines, mean age and comorbidities were higher, and mean TiTR was progressively lower with reducing CrCl strata; (2) the odds ratios for the primary efficacy and safety end points were comparable for the different predefined renal function strata, with nonsignificant trends; and (3) in the subset of those with CrCl ≥95, the odds ratios showed consistency with the other CrCl strata in relation to efficacy versus safety.
Patients with AF and renal impairment represent a high-risk group of patients, with a greater risk of stroke, MI, death, and serious bleeding. 3 As expected, we noted an increase in age and comorbidities, as well as stroke risk, with decreasing CrCl levels. Interestingly, we also observed a small trend toward slightly less good anticoagulation control (but TiTR was still high, ≥68%) at lower CrCl strata, as was seen in other studies showing poorer anticoagulation control with renal impairment. [8] [9] [10] [11] Nonetheless, the efficacy and safety of edoxaban compared with enoxaparin-warfarin remained consistent, irrespective of CrCl strata. Even in the subset of those with CrCl ≥95, the odds ratios showed consistency with the other CrCl strata, with no signal for decreased efficacy and/or safety.
When CrCl was assessed as a continuous variable, there was a nonsignificant trend toward higher major or CRNM bleeding with reducing CrCl levels (as expected and consistent with other studies), 12 with no significant differences between the 2 treatment arms, and the apparent wide CIs, given the low event rates. This observation of higher event rates with lower CrCl is generally consistent with findings from other Phase 3 NOAC trials, notwithstanding the low event rates in these patients.
12,13 The higher event rates in patients with low CrCl may be associated with other comorbidities and perhaps reduced therapeutic control due to increased exposure for renally dependent anti-FXa clearance.
When we assessed CrCl at baseline compared with end of treatment, we observed no significant differences in CrCl change between the edoxaban and enoxaparinwarfarin arms. The proportion of patients with worsening renal function (defined as a decrease of N20% from baseline) was also similar in the 2 treatment arms. In the RE-LY trial, a post hoc analysis showed that renal function decline was worse on warfarin compared with dabigatran 14 ; however, our smaller sample size and shorter follow-up in the present study preclude similar conclusions.
Limitations
This is a prespecified and exploratory ancillary analysis to the ENSURE-AF trial, with consideration of the robust sample size; our observations are limited by the low event rates for the primary efficacy and safety end points. We also had shorter follow-up period compared with the Phase 3 NOAC trials, such that we were unable to fully assess the longer-term impact on renal function of edoxaban compared with enoxaparin-warfarin.
Conclusion
In conclusion, given the small number of events in ENSURE-AF, no apparent effect of renal (dys)function was demonstrated on clinical outcomes when comparing edoxaban to enoxaparin-warfarin for cardioversion; the efficacy and safety of edoxaban remained consistent even in patients with normal or supranormal renal function. Worsening is defined as a decrease of greater than 20% from baseline. ⁎ P value = .2159.
† P value = .3571.
